肺部和肝脏水囊中的翻倍时间
Yener Aydın1, Mesut Özgökçe2, Ali Bilal Ulas1
1Department of Thoracic Surgery, Atatürk University Faculty of Medicine, Erzurum, Türkiye.
Turk gogus kalp damar cerrahisi dergisi
|June 27, 2024
概括
水囊在肺部生长的速度更快 (大约在肺部). 10周),而不是肝脏 (大约. 在25周). 与成年人相比,儿童的囊生长也更快,肺囊在两性之间存在显著差异.
科学领域:
- 寄生虫学的寄生虫学
- 医疗成像医学成像
- 临床医学 临床医学
背景情况:
- 由 Echinococcus granulosus 引起的水囊,是全球严重的健康问题.
- 了解水囊的生长动态对于诊断和治疗规划至关重要.
- 之前的研究没有全面评估影响水囊翻倍时间的因素.
研究的目的:
- 根据患者的年龄,性别和囊位置 (肺与肝脏) 调查水囊翻倍时间的变化.
- 为了比较肺部和肝脏水囊的生长速度.
- 为了确定年龄和性别是否影响不同器官中水囊的翻倍时间.
主要方法:
- 在2012年1月至2023年8月期间,对138个水囊 (55个肺部,83个肝脏) 进行了回顾性分析.
- 数据收集包括患者人口统计 (年龄,性别) 和囊位置.
- 计算并比较不同患者组和囊位置的翻倍时间.
主要成果:
- 肺部水囊的平均翻倍时间 (73.4天) 比肝脏囊 (172.6天) 短得多.
- 儿童的水囊在肺部 (p=0.119) 和肝脏 (p<0.001) 的位置上显示出比成人更快的生长率.
- 在肺囊 (p=0.018) 两性之间观察到翻倍时间的统计学上显著差异,但肝囊 (p=0.250) 没有.
结论:
- 水囊的翻倍时间因位置而异,在肺部的增长速度更快 (约. 10周) 与肝脏 (大约10周) 相比. 在25周).
- 与成年人相比,儿童在肺部和肝脏部位表现出加快的水囊生长.
- 性别影响肺水囊的生长,这表明潜在的性别特异性生物或环境因素会影响寄生虫的发展.
相关概念视频
Hepatic Drug Excretion: Enterohepatic Cycling
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.


